AnaSpec and Cyclex Sign Licensing Agreement for Deacetylase Activity Assay Kits
News Sep 15, 2008
AnaSpec and Cyclex Co. Ltd. have announced a licensing agreement that will allow AnaSpec to make, use, and sell deacetylase activity assay kits and the related products as covered by Cyclex’s patent.
"We are pleased to partner with Cyclex in expanding our array of next generation assay kits," noted Dr. Anita Hong, AnaSpec's president.
"The new SensoLyte™ HDAC assay kits will provide our customers with new long wavelength options for the detection of histone deacetylase activity. AnaSpec also plans to develop other long wavelength HDAC related kits including SIRT assay kits."
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE